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ABSTRACT
Introduction: Toxoplasmosis may be life-threatening in fetuses and in immune-defi cient patients. Conventional laboratory 
diagnosis of toxoplasmosis is based on the presence of IgM and IgG anti-Toxoplasma gondii antibodies; however, molecular 
techniques have emerged as alternative tools due to their increased sensitivity. The aim of this study was to compare the 
performance of 4 PCR-based methods for the laboratory diagnosis of toxoplasmosis. One hundred pregnant women who 
seroconverted during pregnancy were included in the study. The defi nition of cases was based on a 12-month follow-up of 
the infants. Methods: Amniotic fl uid samples were submitted to DNA extraction and amplifi cation by the following 4 
Toxoplasma techniques performed with parasite B1 gene primers: conventional PCR, nested-PCR, multiplex-nested-PCR, and 
real-time PCR. Seven parameters were analyzed, sensitivity (Se), specifi city (Sp), positive predictive value (PPV), negative 
predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and effi ciency (Ef). Results: Fifty-
nine of the 100 infants had toxoplasmosis; 42 (71.2%) had IgM antibodies at birth but were asymptomatic, and the remaining 
17 cases had non-detectable IgM antibodies but high IgG antibody titers that were associated with retinochoroiditis in 8 (13.5%) 
cases, abnormal cranial ultrasound in 5 (8.5%) cases, and signs/symptoms suggestive of infection in 4 (6.8%) cases. The 
conventional PCR assay detected 50 cases (9 false-negatives), nested-PCR detected 58 cases (1 false-negative and 4 false-
positives), multiplex-nested-PCR detected 57 cases (2 false-negatives), and real-time-PCR detected 58 cases (1 false-negative). 
Conclusions: The real-time PCR assay was the best-performing technique based on the parameters of Se (98.3%), Sp (100%), 
PPV (100%), NPV (97.6%), PLR (∞), NLR (0.017), and Ef (99%).
Keywords: Congenital toxoplasmosis. Congenital infection. Molecular diagnosis. PCR. Quantitative PCR. Real-time PCR.
Toxoplasmosis is a worldwide endemic protozoan disease 
that is acquired mainly through infected meat. It is considered 
a major health problem in pregnant women and in immune-
compromised patients. Primary maternal Toxoplasma infection 
may be health-threatening for the fetus, or may even cause death 
in utero, depending on the date of transmission, parasite burden, 
parasite genotype, and host susceptibility. The reactivation of 
a latent infection under immune-defi ciency conditions, such 
as acquired immunodefi ciency syndrome (AIDS) and organ 
transplantation, can cause fatal toxoplasmic encephalitis.
Toxoplasmosis is also an important cause of chorioretinitis, 
especially in individuals with an impaired immune system. In 
these conditions, a rapid and accurate diagnosis is required to 
enable initiation of anti-parasitic treatment as early as possible 
to improve the prognosis1.
While conventional laboratory diagnosis is based on 
serology parameters, such as the presence of IgM and IgG anti-
Toxoplasma antibodies and, to a minor extent, on the parasite 
isolations in mice or in cell culture that are performed only in 
reference centers, molecular techniques, such as polymerase 
chain reaction (PCR), have recently emerged as alternative 
tools to improve the laboratory diagnosis of toxoplasmosis 
due to their increased sensitivity2-4. Therefore, the diagnosis 
of clinically relevant congenital toxoplasmosis now relies on 
molecular techniques, although these techniques are prone to 
performance variation due to a large diversity of target genes and 
primers5, in addition to factors associated with the profi ciency 
of laboratories in the optimization of PCR conditions2.
Recently, the superiority of quantitative amplification 
methods over older techniques, such as one-round and nested-
PCR, has been reported2-4, but there is a lack of information 
regarding the performance of such methods in Brazil.
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RESULTS
METHODS
In an attempt to take the fi rst step toward a consensus on the 
best molecular technique for diagnosing congenital toxoplasmosis 
in Brazilian patients, we compared 4 PCR-based methods performed 
with parasite B1 gene primers, varying from conventional systems 
containing 1 or 2 rounds of amplifi cation to real-time PCR, to 
determine the best-performing technique. The 4 amplification 
methods were based on B1 gene primers because in previous 
experiments analyzing a signifi cant number of amniotic fl uid samples 
of Brazilian women, B1 gene primers performed better than rep529 
and ribosomal deoxyribonucleic acid (rDNA) primers5. 
Study design
One hundred pregnant women receiving prenatal care at 
public hospitals of the State of São Paulo and presenting with 
toxoplasmosis seroconversion, i.e., the presence of positive 
immunoglobulin M (IgM) and signifi cant titers of immunoglobulin 
G (IgG) anti-Toxoplasma gondii antibodies, were screened by 
commercial immune enzyme assays, chemiluminescence, or 
immunofl uorimetry, depending on local availability. This initial 
serology was confi rmed by indirect immunofl uorescence or IgM 
capture according to local laboratory availability and expertise. 
The IgG avidity test was used in 16 of the 100 patients. Exclusion 
criteria were inadequate amniotic fl uid samples, due to mixture 
with either blood or meconium, or sample insuffi ciency. Among 
the 100 pregnant women, 23 underwent amniocentesis during the 
16th week of gestation, 20 during the 17th week, 18 during the 18th 
week, 13 during the 19th week, 5 during the 20th or 21st weeks, 
6 during the 22nd week, 5 during the 23rd week, 3 during the 24th 
week, and 2 during the 25th week of pregnancy. The procedure 
was performed after the women signed informed consent forms 
(Institutional Ethics Committee protocol number 0715/2011). All 
100 women received treatment with 3g/day of spiramycin, which 
was prescribed as soon as the attending physician received the 
serology results and continued until 1 week before the scheduled 
date of delivery to minimize the risk of bleeding. Patients were 
informed of the risks of amniocentesis, as well as the nucleic 
acid procedures that would be performed in the context of the 
research, and the participants consented to all subsequent testing.
Case defi nition
A case of congenital toxoplasmosis was confi rmed when the 
newborn/infant had anti-T. gondii IgM antibodies and/or high 
IgG antibody titers (signifi cantly higher than the maternal titers 
at birth and >300IU/ml in immune enzyme assays at any time 
point) at birth or at some point during the 12-month follow-up. 
In the absence of positive IgM antibodies, high IgG antibody 
titers should be associated with signs and symptoms suggestive 
of toxoplasmosis and/or cranial ultrasound and/or eye fundus 
abnormalities. These complementary tests, together with 
serology, were repeated every 3 months during the follow-up.
DNA extraction and assessment of DNA concentration
Deoxyribonucleic acid (DNA) extraction from amniotic fl uid 
samples was performed with a commercial kit (QIAamp DNA 
mini kit, QIAGEN Inc., Valencia, California, USA) according 
to the manufacturer’s instructions. DNA concentration was 
estimated by ultraviolet (UV) spectrophotometry at 260nm 
(Nanodrop 1000, Thermo Scientifi c, USA).
Amplifi cations
Prior to the specifi c Toxoplasma gondii amplifi cations, 
all DNA samples yielded positive results with human beta-
actin primers6, confi rming that there were no PCR inhibitors 
present. Toxoplasma gondii amplifi cations were performed in 
a total volume of 25µl, consisting of 100ng of amniotic fl uid 
sample DNA, 200µM of dNTP, 0.2µM of primers, 2.0mM of 
MgCL2, and 1.25units of Taq DNA polymerase (GE Healthcare, 
USA), following stringent procedures to minimize the risk of 
carryover7. A total of 40 cycles/round were performed, with 
annealing temperatures of 550C for the outer primer pair JW62/
JW63 and 62ºC for the inner primer pair B22/B23, generating 
amplifi cation products of 286 and 115bp, respectively5. The DNA-
PCR was performed with primers JW62/JW63; the nested-PCR 
was performed with primers JW62/JW63 and B22/B23; and the 
multiplex-nested-PCR was performed with the same JW62/JW63 
and B22/B23 primers used for T. gondii detection and other three 
primer pairs for the simultaneous detection of cytomegalovirus 
(CMV), herpes simplex virus (HSV), and Epstein-Barr 
virus (EBV)8,9. The composition of the parasite B1 gene 
primers was: JW63-GCACCTTTCGGACCTCAACAACCG; 
JW62-TTCTCGCCTCATTTCTGGGTCTA C; B22-
AACGGGCGAGTAGCACCTGAGGAGA; and B23-
TGGGTCTACGTCGATGG ATGACAACT. The fourth 
amplifi cation procedure was a 40-cycle real-time PCR with 
primers B22/B23. The concentrations of primers and template 
DNA were the same as those used for the conventional 
amplifications, and the master mix was prepared with a 
commercial kit (QuantiFast SYBR Green PCR, QIAGEN). 
Cycles were performed at 95°C for 15 seconds at an annealing 
temperature of 62°C for 50sec, ending with temperatures 
between 82 and 83ºC on the melting curve. The slope was 
-3.54; the effi ciency was in the range of 92-100%; and the 
detection limit was 1 parasite in 70% and 10 parasites in 100% of 
experiments (Thermocycler Step One Plus, Applied Biosystems, 
Foster City, California, USA). Samples were tested in triplicate 
with real-time PCR, but results were considered only in a binary 
manner (positive or negative).
All 100 women in the study had positive IgM and IgG anti-
T. gondii antibodies as assessed by screening serology and also 
by a confi rmatory test. Unfortunately, the IgG avidity test results 
could not be used to aid the laboratory diagnosis because these 
data were only available for 16 of the 100 patients, and the percent 
avidity was inconclusive in 10 of these 16 cases (data not shown).
The assessment of newborns by clinical, serological, and 
complementary exams and the monitoring of infants until the 
age of 12 months revealed that among the 100 total cases, 59 
had confi rmed toxoplasmosis; 42 (71.2%) newborns had IgM 
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DISCUSSION
TABLE 1 - The performance of 4 PCR-based techniques for the molecular diagnosis of congenital toxoplasmosis. 
  Se Sp PPV NPV 
Technique (95% CI) (95% CI) (95% CI) (95% CI) PLR NLR Ef (%)
Conventional PCR 84.7 100.0 100.0 82.0 § 0.15 91.0
 (0.73 – 0.93) (0.91 – 1.00) (0.94 -1.00) (0.69 – 0.91)   
Nested PCR 98.3 90.2 93.5 97.4 10.07 0.018 95.0
 (0.91 – 0.99) (0.77 – 0.97) (0.84 – 0.98) (0.86 – 0.99)   
Multiplex-nested-PCR 96.6 100.0 100.0 95.3 § 0.034 98.0
 (0.88 – 0.99) (0.91 – 1.00) (0.94 – 1.00) (0.84 -0.99)   
Real-time PCR 98.3 100.0 100.0 97.6 § 0.017 99.0
 (0.91 – 0.99) (0.91 – 1.00) (0.94 – 1.00) (0.87 – 0.99)   
Se: sensitivity; Sp: specifi city; PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative 
likelihood ratio; Ef: effi ciency; PCR: polymerase chain reaction; §: infi nite; CI: confi dence interval.
antibodies at birth but were asymptomatic, and the remaining 
17 (28.8%) newborns had high IgG titers (> 300IU/ml) in 
the serology tests. These high titers were associated with 
chorioretinitis in 8 (13.5%) infants; abnormal cranial ultrasound 
in 5 (8.5%) infants; and signs/symptoms suggestive of infection, 
such as marked jaundice, hepatomegaly, and splenomegaly that 
regressed after treatment, in 4 (6.8%) infants. Among the 59 
confi rmed cases, 50 were positive based on conventional PCR 
(9 false-negative results and no false-positive results), 58 based 
on nested-PCR (1 false-negative and 4 false-positive results), 
57 based on multiplex-nested-PCR (2 false-negative results 
and no false-positive results), and 58 based on real-time PCR 
(1 false-negative and no false-positive results). 
Parameters of sensitivity (Se), specificity (Sp), positive 
predictive value (PPV), negative predictive value (NPV), positive 
likelihood ratio (PLR), negative likelihood ratio (NLR) and 
effi ciency (Ef) of the 4 amplifi cation techniques were analyzed 
based on the confi rmation of positive and negative cases according 
to their clinical and laboratory evolution until the age of 12 
months. The 7 analyzed parameters are displayed in Table 1.
The effectiveness of different target genes and primers 
in the amplifi cation of T. gondii DNA in different types of 
biological samples has long being evaluated in the literature; 
however, there is a lack of consensus on this topic, at least in 
non-European countries, and performance is strongly dependent 
on the proficiency of laboratories in the optimization of 
the PCR2,5.
Reischl et al.10, in a European study, used real-time PCR 
(LightCycler) with rep529 and B1 gene primers to evaluate 51 
Toxoplasma gondii-positive amniotic fl uid samples and found 
a 10-100-fold higher sensitivity for the PCR assay that targeted 
the 529-bp repeat element of Toxoplasma gondii.
Edvinsson et al.11, also in Europe, investigated whether real-
time PCR could be used to monitor parasitemia in the blood 
of a transplant recipient presenting with toxoplasmosis. The 
results demonstrated that detection of the 529-bp repeat element 
increased the diagnostic sensitivity and accuracy compared with 
the assessment of the B1 gene only. These authors also added an 
internal amplifi cation control that did not apparently affect the 
PCR performance and was useful for monitoring PCR inhibition 
by non-specifi c DNA in the LightCycler instrument.
One of the fi rst Brazilian studies on the molecular diagnosis 
of congenital toxoplasmosis was conducted by Vidigal et al.12 
in 2005. The authors analyzed 86 amniotic fl uid samples from 
women who seroconverted during pregnancy in the State of 
Minas Gerais. Samples were inoculated in mice and submitted to 
T. gondii DNA amplifi cation by a nested-PCR. Newborns were 
also evaluated by T. gondii serology, skull x-ray, transfontanel 
ultrasound, fundoscopic examination, and lumbar puncture. 
PCR was positive in 7 cases and negative in 79 (7/86 or 8.1%) 
cases. Among the PCR-positive cases, two were negative after 
mouse inoculation; among the PCR-negative cases, 3 had 
clinical evidence of toxoplasmosis and 1 was positive after 
mouse inoculation. PCR showed a sensitivity of 62.5% and 
specifi city of 97.4% whereas mouse inoculation had a sensitivity 
of 42.9% and a specifi city of 100%. At that time, the authors 
considered PCR to be a promising diagnostic method.
In 2009, Okay et al.5 conducted a study in the State of 
São Paulo, Brazil. They analyzed 467 amniotic fl uid samples 
from women who had seroconverted during pregnancy and 
found 189 (40.5%) positive samples by one-round amplifi cations: 
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120 (63.5%) with the T. gondii B1 gene, 24 (12.7%) with the 
parasite AF146527 sequence (also called rep529), 45 (23.8%) 
with both, rep529 and the B1 gene, and none with rDNA 
(ribosomal DNA). In the same study, 50 previously negative 
one-round PCR samples were chosen by computer-assisted 
randomization analysis and were re-tested by a nested-PCR 
based on the parasite B1 gene, which detected 9 additional 
cases (9/50 or 18%). The authors concluded that there was 
signifi cant performance variation among one-round and nested-
amplifi cation systems and showed that the most sensitive method 
of those tested was a nested-PCR assay with the outer primers 
JW62/JW63 and the inner primers B22/B23 from the parasite 
B1 gene compared with other target genes, such as rep529, and 
rDNA. However, in those experiments, the rep529 primers and 
amplifi cation products were not suitable for real-time PCR.
In contrast, some studies reported an increased sensitivity 
of PCR targeting the rep529 sequence over that of the B1 gene2-
4; these fi ndings were corroborated by Menotti et al.13, who 
developed a new 5’-nuclease real-time PCR assay targeting 
the rep529 sequence (TaqMan-rep529-PCR) to diagnose 
toxoplasmosis and assess treatment follow-up. Initially, these 
authors analyzed 144 clinical specimens for the presence 
of T. gondii DNA by a polymerase chain reaction-enzyme-
linked immunosorbent assay (PCR-ELISA) assay targeting 
the parasite B1 gene (B1-PCR-ELISA) and found 15 positive 
samples, all of which were from patients with clinically proven 
toxoplasmosis that were negative by the B1-PCR-ELISA and 
positive according to the TaqMan- rep529 -PCR. Then, the 
same authors analyzed 203 consecutive clinical specimens 
during a 4-month period. The diagnosis of toxoplasmosis in two 
patients was made only by the TaqMan-rep529-PCR and not 
by the B1-PCR-ELISA. Additionally, samples from a patient 
with cerebral and disseminated toxoplasmosis, who had already 
been tested using a B1 real-time PCR assay, were evaluated by 
the TaqMan-rep529-PCR in a Light Cycler real-time PCR assay 
targeting the same repetitive rep529 sequence. The TaqMan-
rep529-PCR assay was able to detect positive samples and had 
a mean gain of 7.1 following 3.3 amplifi cation cycles compared 
with the B1 real-time PCR assay. These authors concluded that 
the 5’-nuclease real-time PCR assay developed for the rep529 
sequence was more sensitive than those using the B1 gene.
However, Wahab et al.14 showed that the rep529 element was 
absent in 4.8% of human T. gondii-positive samples, suggesting 
that the B1 gene should be considered a preferred diagnostic 
target. Nevertheless, the rep529 sequence has been the most used 
sequence in European studies, including a study that analyzed 
the performance of 3 molecular methods for the amplifi cation of 
T. gondii DNA in amniotic fluid samples, namely a commercial 
kit (nested-PCR) and two in-house methods (a conventional 
PCR and a real-time PCR). This evaluation was based on a 
T. gondii DNA serial dilution, 3 amniotic fluid samples 
inoculated with T. gondii at different concentrations, and 33 
amniotic fluid samples from a clinical cohort. The T. gondii DNA 
serial dilution assay showed a much lower sensitivity for the 
commercial kit than for the two in-house methods. Moreover, of 
the 12 proven congenital toxoplasmosis cases among the cohort, 
91.7% were detected by the in-house assays, whereas only 50% 
were detected by the commercial kit15. This lack of sensitivity 
was  attributed to the presence of PCR inhibitors.
In a recent Brazilian study16, a real-time PCR (qPCR) 
targeting the parasite rep529 sequence was positive in 72 (48%) 
blood samples from 150 infected newborns. Among the infants 
with active retinochoroiditis, 68% had positive qPCR results, 
while positivity was much lower (29%, p=0.009) in the absence 
of ocular involvement. The authors concluded that the qPCR 
acted as a prognostic factor and that the positivity of samples 
was associated with the presence of retinochoroidal lesions, with 
an odds ratio of 2.8. In that study, it is clear that the qPCR assay 
was used to evaluate the prognosis of newborns with respect to 
eye injuries and was not used for the purpose of diagnosis, given 
that the biological material used was blood. This methodology 
explains the low (48%) percentage of newborns with confi rmed 
congenital toxoplasmosis and positive qPCR results, contrasting 
with the 58/59 confi rmed cases (98.3%) detected in the amniotic 
fl uid samples of the present study. Nevertheless, as the target 
gene (rep529 sequence versus B1 gene) and the biological 
material (peripheral blood versus amniotic fluid samples) 
were different, prospective studies comparing real time PCR 
performed with rep529 primers or B1 gene primers in the same 
type of biological samples are needed. It is also important to 
clarify that the rep529 pair of primers tested in our laboratory 
in the experiments published in 20095 are not suitable for real-
time PCR, contrasting with the rep529 primers described in that 
recently published Brazilian report13.
In the present study, 100 women who seroconverted during 
pregnancy were included in the study. Among the 100 suspected 
cases, 59 were confi rmed and 41 were excluded after a 12-month 
follow-up during which the infants were clinically re-evaluated 
and also analyzed by means of serology, as well as other exams, 
e.g., ocular fundoscopy and cranial ultrasound or computerized 
tomography in older infants, repeated every 3 months. Amniotic 
fl uid samples were subjected to 4 different molecular tests 
performed with the parasite B1 gene primers, always by the 
same technician in the same laboratory facility. Importantly, 
neither technique was able to detect all 59 confi rmed cases 
in this study. However, it is important to mention that we did 
not stratify the cases according to gestational age at the time 
of transmission, and this parameter seems to be a determinant 
of the positivity found by different molecular methods in the 
congenital toxoplasmosis model. For example, Sterkers et al.17 
analyzed the performance of an optimized PCR assay tested on 
amniotic fluid samples, placenta, and cord blood in a cohort of 
344 pregnant women who underwent amniocentesis and whose 
children were followed for 1 year. The authors analyzed the PCR 
results according to the gestational age at the time of maternal 
infection and inferred accurate post-test predictive values for 
diagnosis. They concluded that despite the persistence of false-
negatives, using a highly accurate molecular diagnostic test 
and the post-test risk curves, it is possible to predict the actual 
risk of congenital toxoplasmosis at different gestational ages.
According to the analyzed parameters for the 4 molecular 
techniques and the TDR (UNICEF, UNDP, World Bank, WHO) 
recommendations developed to guide laboratory diagnostic 
procedures, including Nucleic Acid Tests (NATs)18, DNA-PCR 
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should not be used due to its relatively low (84.7%) sensitivity. 
This technique failed to detect 9 positive cases, but it did not 
yield any false-positive results. The nested-PCR technique had a 
specifi city of 90.2% and thus did not meet the specifi city criterion 
for laboratory diagnostic procedures (specifi city >95%). It also 
produced 4 false-positive results, possibly caused by carry-
over, which is a known drawback of this type of amplifi cation, 
even when performed by experienced individuals7. Among the 
methods that complied with the recommended sensitivity and 
specifi city levels, i.e., the multiplex-nested-PCR and real-time 
PCR techniques, the multiplex-nested-PCR did not produce any 
false-positive results but detected 1 fewer case than the nested-
PCR technique, even though both techniques were performed 
with the same Toxoplasma primer pairs. This difference was 
most likely due to competition for the use of reagents, as there 
were 4 primer pairs in each multiplex-nested-PCR to allow for 
simultaneous detection of T. gondii, CMV, HSV, and EBV8,9. 
Among the 4 proposed methods, the real-time PCR technique 
detected 58 of the 59 possible cases did not produce any false-
positive results and was the best-performing test considering 
all 7 analyzed parameters, a sensitivity of 98.3%, specifi city of 
100%, PPV of 100%, NPV of 97.6%, an infi nite PLR, a NLR of 
0.017, and an effi ciency of 99%, corroborating the fi ndings of 
previous studies2-4 that highlighted the advantages of real-time 
PCR. Moreover, this technique is able to determine the number 
of parasites/target gene copy number, enabling follow-up of 
treated patients, and has a short run time, reducing the risk of 
carry-over and handling of DNA intercalating substances.
In conclusion, in this study performed on 100 amniotic fl uid 
samples from pregnant women living in the State of São Paulo, 
the best-performing technique, based on the parameters of 
sensitivity, specifi city, positive and negative predictive values, 
positive and negative likelihood ratios, and effi ciency, was the 
real-time PCR technique with primers B22/23. In the future, 
we intend to analyze these same amniotic fl uid samples with 
primers of the parasite rep529 sequence using real-time PCR 
to compare our results with those of other studies.
The authors declare that there is no confl ict of interest.
CONFLICT OF INTEREST
FINANCIAL SUPPORT
This work was supported by FAPESP (Fundação de Amparo à 
Pesquisa do Estado de São Paulo; grant number 2010/15022-1), 
as well as by CNPq (Conselho Nacional de Desenvolvimento 
Científi co e Tecnológico; grant number 2011-0/471479).
REFERENCES
1. Montoya JG, Remington JS. Management of Toxoplasma gondii infection 
during pregnancy. Clin Infect Dis 2008, 47:554-566.
2. Sterkers Y, Varlet-Marie E, Cassaing S, Brenier-Pinchart MP, Brun S, 
Dalle F, et al. Multicentric comparative analytical performance study for 
molecular detection of low amounts of Toxoplasma gondii from simulated 
specimens. J Clin Microbiol 2010; 48:3216-3222.
3. Nagy B, Bán Z, Beke A, Nagy GR, Lázár L, Papp C, et al. Detection of 
Toxoplasma gondii from amniotic fl uid, a comparison of four different 
molecular biological methods. Clin Chim Acta 2006; 368:131-137.
4. Cassaing S, Bessières MH, Berry A, Berrebi A, Fabre R, Magnaval JF. 
Comparison between two amplifi cation sets for molecular diagnosis of 
toxoplasmosis by real-time PCR. J Clin Microbiol 2006, 44:720-724.
5. Okay TS, Yamamoto L, Oliveira LC, Manuli ER, Andrade Jr HF, Del 
Negro GM. Signifi cant performance variation among PCR systems in 
diagnosing congenital toxoplasmosis in São Paulo, Brazil: analysis of 467 
amniotic fl uid samples. Clinics 2009; 64:171-176.
6. Nakajima-Iljima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of 
the human cytoplasmic β-actin gene: interspecies homology of sequences in the 
introns. Proc Natl Acad Sci USA 1985; 82:6133-6137.
7. Rolfs A, Schuller I, Finckh U, Weber-Rolfs I. PCR contamination and 
falsely interpreted results. Editor Arndt Rolfs. PCR: clinical diagnostics 
and research. Berlin: Springer-Verlag 1992; p. 61-67.
8. Camargo PR, Okay TS, Yamamoto L, Del Negro GM, Lopes AA. 
Myocarditis in children and detection of viruses in myocardial tissue: 
implications for immunosuppressive therapy. Int J Cardiol 2011; 148:
204-208.
9. Mendes TM, Oliveira LC, Yamamoto L, Del Negro GMB, Okay TS. Epstein-
Barr Virus nuclear antigen-2 detection and typing in immunocompromised 
children correlated with lymphoproliferative disorder biopsy fi ndings. Braz J 
Infect Dis 2008; 12:186-191.
10. Reischl U, Bretagne S, Krüger D, Ernault P, Costa J-M. Comparison of 
two DNA targets for the diagnosis of toxoplasmosis by real-time PCR 
using fl uorescence resonance energy transfer hybridization probes. BMC 
Infectious Diseases 2003; 3:1-9.
11. Edvinsson B, Lappalainen M, Evengard B, on behalf of the ESCMID 
Study Group for Toxoplasmosis. Real-time PCR targeting a 529-bp repeat 
element for diagnosis of toxoplasmosis. Clin Microbiol Infect 2006; 
12:131-136.
12. Vidigal PVT, Santos DVV, Castro FC, Couto JCF, Vitor RWA, Brasileiro-
Filho G. Prenatal toxoplasmosis diagnosis from amniotic fl uid by PCR. 
Rev Soc Bras Med Trop 2002; 35:1-6.
13. Menotti J, Garin Y. J-F, Thulliez P, Sérugue M-C, Stanislawiak J, Ribaud 
P, et al. Evaluation of a new 5’nuclease real-time PCR assay targeting 
the Toxoplasma gondii AF146527 genomic repeat. Clin Microbiol Infect 
2010; 16:363-368.
14. Wahab T, Edvinsson B, Palm D, Lindh J. Comparison of the AF146527 
and B1 repeated elements, two real-time PCR targets used for detection of 
Toxoplasma gondii. J Clin Microbiol 2010; 48:591-592.
15. Morelle C, Varlet-Marie E, Brenier-Pinchart MP, Cassaing S, Pelloux H, 
Bastien P, et al. Comparative assessment of a commercial kit and two 
laboratory-developed PCR assays for molecular diagnosis of congenital 
toxoplasmosis. J Clin Microbiol 2012; 50:3977-3982.
16. Costa JG, Carneiro AC, Tavares AT, Andrade GM, Vasconcelos-Santos 
DV, Januário JN, et al. Real-time PCR as prognostic tool of human 
congenital toxoplasmosis. J Clin Microbiol 2013; Jun 12. [Epub ahead 
of print].
17. Sterkers Y, Pratlong F, Albaba S, Loubersac J, Picot M-C, Pretet V, et al. 
Novel interpretation of molecular diagnosis of congenital toxoplasmosis 
according to gestational age at the time of maternal infection. J Clin 
Microbiol 2012; 50:3944-3951.
18. The TDR Diagnostics Evaluation Expert Panel. Evaluation of diagnostic 
tests for infectious diseases: General principles. Nature Reviews/
Microbiology, Macmillan Publishers Limited, S17-S29, December 
2010.
Rev Soc Bras Med Trop 46(5):584-588, Sep-Oct, 2013
